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Abstract
Background: During the 2009-2010 pandemic in Norway, 12 513 laboratory-confirmed cases of pandemic
influenza A(H1N1)pdm09, were reported to the Norwegian Surveillance System for Communicable Diseases (MSIS).
2.2 million persons (45% of the population) were vaccinated with an AS03-adjuvanted monovalent vaccine during
the pandemic. Most of them were registered in the Norwegian Immunisation Registry (SYSVAK). Based on these
registries, we aimed at estimating the vaccine effectiveness (VE) and describing vaccine failures during the
pandemic in Norway, in order to evaluate the role of the vaccine as a preventive measure during the pandemic.
Methods: We conducted a population-based retrospective cohort study, linking MSIS and SYSVAK with pandemic
influenza vaccination as exposure and laboratory-confirmed pandemic influenza as outcome. We measured VE by
week and defined two thresholds for immunity; eight and 15 days after vaccination.
Results: The weekly VE ranged from 77% to 96% when considering 15 days or more after vaccination as the threshold
of immunity and from 73% to 94% when considering eight days or more. Overall, 157 individuals contracted pandemic
influenza eight or more days after vaccination (8.4/100,000 vaccinated), of these 58 had onset 15 days or more after
vaccination (3.0/100,000 vaccinated). Most of the vaccine failures occurred during the first weeks of the vaccination
campaign. More than 30% of the vaccine failures were found in people below 10 years of age.
Conclusions: Having available health registries with data regarding cases of specific disease and vaccination makes
it feasible to estimate VE in a simple and rapid way. VE was high regardless the immunity threshold chosen. We
encourage public health authorities in other countries to set up such registries. It is also important to consider
including information on underlying diseases in registries already existing, in order to make it feasible to conduct
more complete VE estimations.
Background
During the 2009-2010 influenza pandemic, surveillance
for influenza in Norway was enhanced: laboratory-con-
firmed infection with the new A(H1N1)pdm09 virus was
defined as a mandatory notifiable disease on a case
based level. During the pandemic, doctors from all
health care settings were encouraged to swab patients
with suspected influenza and submit the samples to
their nearest clinical microbiology laboratory. Each
laboratory-confirmed case had to be notified to the Nor-
wegian Institute of Public Health (NIPH), where it was
registered in the Norwegian Surveillance System for
Communicable Diseases (MSIS) with the unique perso-
nal identification number (PIN). Criteria for sampling
suspected cases changed during the pandemic. During
the first months of the pandemic (from May until Octo-
ber 2009) all suspected cases were sampled. However, as
the pandemic developed and number of cases increased,
only those that belonged to risk groups or with severe
influenza like illness (ILI) symptoms were sampled since
it was no longer feasible to swab all suspected cases. In
total, 12,513 influenza A(H1N1)pdm09 laboratory-
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pandemic (May 2009-April 2010). The first scattered
cases were recorded in early May 2009 among travellers
returning from countries where the virus was already
circulating. In July and August (weeks 26-35) a first
wave occurred. The second and main wave during Octo-
ber and November (weeks 43-49) reached a higher peak.
From December the number of cases decreased until
April 2010, when the last cases were reported [1].
On 19 October 2009, just before the main wave of the
pandemic, the vaccination campaign against influenza A
(H1N1)pdm09 started in Norway with vaccine available
from GlaxoSmithKline Biologicals S.A. (GSK) through
an advance purchase agreement. Some days before, on
25 September 2009, the European Medicines Agency
(EMA) had recommended marketing authorisation of
GSK’s AS03-adjuvanted monovalent vaccine containing
3.75 micrograms of hemagglutinin antigen per dose [2].
The vaccine contained the influenza strain A/California/
7/2009 (H1N1) [3]. At the beginning, two doses were
recommended by EMA based on data on the mock up
vaccine, containing an A(H5N1) virus strain [4]. How-
ever, clinical trials containing A(H1N1)pdm09 indicated
that one dose would provide sufficient immunogenicity
in most formulations [2] and the recommendation was
therefore changed at the end of October 2009. At the
beginning of the vaccination campaign in Norway only
health care workers, pregnant women and children and
adults with certain underlying diseases were recom-
mended to be vaccinated. The recommendation was
expanded to the whole population over six months of
age on 23 October 2009 [5,6].
The Norwegian Immunisation Registry (SYSVAK),
where all the vaccinations given in the childhood
i m m u n i s a t i o np r o g r a m m ei nN o r w a yh a v er o u t i n e l y
been registered since 1995, was adapted for registration
of vaccination against A(H1N1)pdm09 during the pan-
demic. A new Internet based registration module with
automatic linkage to the national population registry
containing the PIN of all individuals in Norway was
created. The Ministry of Health and Care Services
decided in October 2009, just before the start of the
vaccination campaign, that there should be mandatory
notification to SYSVAK of all vaccinations against pan-
demic influenza. An estimate by the Norwegian health
authorities indicated that 2.2 million people (45% of
the total population) were vaccinated during the cam-
paign [7]. Most of them, 1,963,895 persons, were noti-
fied to SYSVAK.
We aimed to estimate the vaccine effectiveness (VE)
of the AS03-adjuvanted monovalent vaccine (from now
called “pandemic influenza vaccine”) against laboratory-
confirmed influenza A(H1N1)pdm09 and describe the
individuals who had laboratory-confirmed influenza in
spite of vaccination (vaccine failures) during the 2009-
2010 influenza pandemic in Norway.
Methods
We conducted a population-based retrospective cohort
study during the main wave of the pandemic, from
October 2009 until December 2009.
Laboratory-confirmed cases of A(H1N1)pdm09 influ-
enza registered in MSIS were linked to their vaccination
s t a t u si nS Y S V A Kb yt h eu n i q u eP I N .B o t hr e g i s t r i e s
were created for surveillance purposes and are managed
by the Division of Infectious Disease Control at the
NIPH. Ethical approval was not required as updating of
MSIS with the patients’ vaccination histories from SYS-
VAK is part of the quality assurance of MSIS.
For analysis the following variables of interest were
extracted from MSIS: sex, county of residence, year of
birth, date of onset of influenza and date of laboratory
testing. For those cases in which the real date of onset
of symptoms was unknown, a proxy date of onset was
estimated by subtracting two days (average of days
between date of onset and date of laboratory testing in
those cases in which both real dates were known) from
the date of laboratory testing. The date of vaccination
was extracted from SYSVAK and added to the MSIS
dataset. After this, the PIN was deleted which anon-
ymised the data used for analysis.
In order to measure VE, the exposure of interest was
vaccination against influenza A(H1N1)pdm09. Since
previous studies differ on the time needed to achieve
full immunity against influenza after vaccination [8-10],
we considered two different thresholds for immunity in
our study: eight or more days and 15 or more days after
vaccination. The outcome of interest was laboratory-
confirmed influenza A(H1N1)pdm09. A case was
defined as “a person with influenza A(H1N1)pdm09
infection confirmed by laboratory using reverse tran-
scription-polymerase chain reaction (RT-PCR), regis-
tered in MSIS”. Vaccine effectiveness (VE) of the
pandemic influenza vaccine was measured with the fol-
lowing formula [9]:
VE = 1−
Cumulative Incidence of inﬂuenza A(H1N1)pdm09 in vaccinated population
Cumulative Incidence of inﬂuenza A(H1N1)pdm09 in unvaccinated population
As the number of cases and the number of persons
vaccinated changed through the pandemic period, we
measured VE overall and by week starting from week
45, when considering 15 days or more as the immunity
threshold and from week 44 when considering eight
days or more. People who had already had laboratory-
confirmed influenza were removed from the denomina-
tor in the following weeks.
We extracted the aggregated total number of people
vaccinated by week from SYSVAK. We obtained the
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2009 from Statistics Norway http://www.ssb.no.
We describe in more detail those individuals who had
laboratory-confirmed influenza in spite of vaccination at
least eight or 15 days earlier (vaccine failures).
Results
When considering 15 days or more after vaccination as
the threshold of immunity, VE by week ranged from
77% (95%CI 64%-86%) in week 48 to 96% (95%CI 71%-
99%) in week 50. In week 51, VE was 100% since there
were no vaccinated laboratory-confirmed cases reported
(Table 1). When we estimated VE considering eight
days or more after vaccination as the threshold, VE by
week ranged from 73% (95%CI 63%-80%) in week 45 to
94% (95%CI 58%-99%) in week 51 (Table 2).
A total of 157 individuals were considered vaccine fail-
ures, i.e. they had onset of symptoms of pandemic influ-
enza eight days or more after vaccination (8.4 per
100,000 vaccinated). When defining vaccine failure as
those who had onset 15 days or more after vaccination,
the number of vaccine failures decreased to 58 (3.0 per
100,000 vaccinated). There were slightly more females
than males: 33 (52%) when using 15 days or more as
the immunity threshold and 81 (57%) when using eight
days. Most of the vaccine failures occurred during the
first weeks of the vaccination campaign. After week 46,
the proportion of failures decreased gradually to become
minimal during the last weeks of the year (Figure 1).
The highest proportion of vaccine failures was
observed among persons less than 10 years of age: 19
cases (33% of all vaccine failures) when considering the
threshold 15 days and 65 cases (41%) when considering
eight days. When moving the threshold from 15 to eight
days the largest increase of vaccine failures was observed
in the 0-9 years age group (increasing from 5.3 to 18.2
per 100,000 vaccinated), among those aged 50-59 years
(increasing from 3.6 to 10.4 per 100,000 vaccinated) and
those older than 70 years (increasing from 0.5 to 3.1 per
100,000 vaccinated) (Figure 2).
Discussion
Pre-existing national health registries created for surveil-
lance purposes allowed us to estimate VE and describe
vaccine failures during the 2009-2010 influenza pan-
demic. Our results show that vaccination with an AS03-
adjuvanted monovalent vaccine against A(H1N1)2009
conferred a very high protective effectiveness against
laboratory confirmed pandemic influenza in Norway,
regardless of immunity threshold chosen.
We measured VE by week in order to take account of
the changes in the denominators over time as when
more people were vaccinated. An overall calculation
with fixed denominators would have yielded VE of 99%
and 97% with 15 and eight days immunity thresholds,
respectively. This underlines that, in specific scenarios,
such as a pandemic situation where a vaccine is not dis-
tributed simultaneously to the whole population, VE
should always be estimated taking into account time in
order to avoid an overestimated measurement of the
protection provided by the vaccine. Controlling by time
has already shown to be useful when estimating VE in
the pandemic in other published studies [10]. Together
with time, age is a critical factor when determining VE.
However, due to the low number of influenza cases
notified per week in each age-group, we were not able
to adjust our VE estimates by age.
There are some intrinsic characteristics of the national
health registries used in our study that should be taken
into account when interpreting our results. MSIS does
not include all pandemic influenza cases that occurred
in Norway, since at the time when the vaccination
Table 1 Estimated effectiveness of the pandemic influenza vaccine during the main wave of the influenza pandemic in
Norway.
Week 45 46 47 48 49 50 51 52 53
Vaccinated population
No of cases 1 14 19 17 2 1 0 1 3
Population 32,766 266,278 501,115 698,006 873,629 1,105,763 1,397,506 1,675,354 1,891,980
Incidence(per 100,000) 3.05 5.26 3.79 2.44 0.23 0.09 0.00 0.06 0.16
Unvaccinated population
No of cases 2579 1612 866 453 187 84 34 16 12
Population 4,811,608 4,575,516 4,339,053 4,141,277 3,965,184 3,732,861 3,441,033 3,163,151 2,946,508
Incidence(per 100,000) 53.60 35.23 19.96 10.94 3.72 2.25 0.99 0.51 0.41
Vaccine effectiveness
Point estimate 94% 85% 81% 77% 95% 96% 100% 88% 61%
95% confidence interval 60%-99% 75%-90% 70%-88% 64%-86% 64%-99% 71%-99% - 11%-92% -37%-89%
Estimated effectiveness of AS03-adjuvanted monovalent vaccine during the main wave (weeks 45-53, 2009) of the influenza pandemic in Norway Vaccinees were
considered immune 15 days and later after vaccination.
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toms or those that belonged to a risk group were
sampled. This means that the laboratory-confirmed
cases notified in MSIS are not a random sample of all
the cases occurring in the Norwegian population. If the
likelihood of having laboratory-confirmed influenza and
thus be notified to MSIS, was associated with vaccina-
tion status, our VE estimate could be biased. It should
also be noted that not all vaccinations were notified to
SYSVAK. Overall, the number of vaccinated population
shown in Table 1 and Table 2 is expected to be around
10% higher, leading to an even lower incidence among
those vaccinated. With other factors being equal, this
effect alone will have led to an underestimation of the
VE.
This study is also subject to other potential biases.
Firstly, at the beginning of the pandemic period only
groups at risk were recommended to be vaccinated.
Patients with underlying conditions, like immunity dis-
orders, may have had a lower response to the vaccine.
This would result in an underestimation of the VE. This
bias is known as confounding by indication. Our results
may reflect this, since the proportion of vaccine failures
during the first weeks after the vaccination campaign
started is the highest during the whole period.
Secondly, the opposite effect, an overestimation of VE
can be seen if healthy people were more likely to be
vaccinated. This situation is known as healthy vaccinee
confounding and may have occurred in the period when
vaccination was recommended to the general population
Table 2 Estimated effectiveness of the pandemic influenza vaccine during the main wave of the influenza pandemic in
Norway.
Week 44 45 46 47 48 49 50 51 52 53
Vaccinated population
No of cases 3 40 45 31 21 75113
Population 32,766 266,276 501,087 697,952 873,561 1,105,676 1,397,413 1,675,256 1,891,882 1,891,654
Incidence(per 100,000) 9.16 15.02 8.98 4.44 2.40 0.63 0.36 0.06 0.05 0.16
Unvaccinated population
No of cases 2683 2540 1,581 854 449 182 80 33 16 12
Population 4,811,608 4,575,412 4,338,021 4,139,530 3,963,036 3,730,451 3,438,525 3,160,597 2,943,937 2,919,148
Incidence(per 100,000) 55.76 55.51 36.45 20.63 11.33 4.88 2.33 1.04 0.54 0.41
Vaccine effectiveness
Point estimate 84% 73% 75% 78% 79% 87% 85% 94% 90% 62%
95% confidence interval 50%-95% 63%-80% 67%-82% 69%-85% 68%-86% 72%-99% 62%-94% 58%-99% 27%-99% -34%-90%
Estimated effectiveness of AS03-adjuvanted monovalent vaccine during the main wave (weeks 44-53, 2009) of the influenza pandemic in Norway. Vaccinees were
considered immune eight days and later after vaccination.
Figure 1 Rates of vaccine failures per week and overall during the main wave of the influenza pandemic in Norway. Rates of vaccine
failures (per 100,000 vaccinated) per week and overall of the AS03-adjuvanted monovalent vaccine during the main wave (weeks 45-53, 2009) of
the influenza pandemic in Norway. Blue bars indicate immunity as eight days and later after vaccination; red bars as 15 days and later.
Guzmán Herrador et al. BMC Infectious Diseases 2012, 12:63
http://www.biomedcentral.com/1471-2334/12/63
Page 4 of 6and most of the people in the risk groups had already
been vaccinated. There are some indications of this bias
in our results since the VE estimate improved as the
vaccination campaign moved on.
Thirdly, clinicians may have been less likely to test for
influenza in patients known to be vaccinated, thinking
that influenza was an unlikely cause of their symptoms.
Due to this potential diagnostic bias, vaccine failures
may have been missed and VE overestimated. However,
the NIPH encouraged clinicians to document suspected
vaccine failures by testing in order to minimize this bias.
Finally, as the campaign developed, more and more
persons were immune due to vaccination or natural
immunity following infection. This probably led to some
degree of herd protection, which may also have had an
effect on the measured VE.
Our results are in concordance with findings of pub-
lished meta-analyses of randomized trials of influenza
vaccines [11,12]. They are also consistent with the con-
clusions of previous pandemic influenza VE studies con-
ducted in other European countries [9,13-16] and
Canada [17], where it was concluded that, overall, the
pandemic influenza vaccine was highly effective in pre-
venting laboratory-confirmed infection with pandemic
influenza A(H1N1)pdm09. Our study also supports find-
ings in of previous preliminary studies conducted in
Norway during the pandemic period [18].
Regardless the high VE measured, our results highlight
specific age groups that seemed to be less protected by
the vaccine and in need of more time to develop immu-
nity. Special attention should be paid to those less than
10 years of age due to high number of people involved.
However, in order to be able to recommend specific
precautions after vaccination in this age group, further
studies controlling for potential confounding factors
(like underlying diseases) should be carried out. The
nature of our study, using already available register
based information, did not allow us to control for such
factors.
We used two existing registries for this study. MSIS,
the infectious disease register, was augmented during
t h ep a n d e m i cb yi n c l u s i o no fl a b o r a t o r y - c o n f i r m e d
influenza A(H1N1)pdm09 as notifiable disease on a case
based level. This mainly served surveillance purposes
and for informing the public health response, but the
data could also be used for evaluation of the interven-
tions put in place, as shown in this study. The cost of
the augmentation was small as already existing proce-
dures and infrastructure was used. SYSVAK, the immu-
nisation register, was augmented by including pandemic
vaccination. The purpose of this was both to monitor
the execution of the vaccination campaign and to pre-
pare for follow-up studies. A web-based platform was
introduced and linked to the national population regis-
ter to facilitate easy entry of each vaccination by the
vaccinators. The time needed for entry of one vaccina-
tion was less than 30 seconds. Because of the high num-
ber of vaccinations, however, the total time spent on
registrations was considerable.
Conclusions
We have shown that available health registries with sur-
veillance data on infectiousd i s e a s e sa n dv a c c i n a t i o n
made it feasible to estimate VE in a simple and rapid
Figure 2 Rates of vaccine failures by age group and overall during the main wave of the influenza pandemic in Norway.R a t e so f
vaccine failures (per 100,000 vaccinees) by age group and overall of the AS03-adjuvanted monovalent vaccine during the main wave (weeks 45-
53, 2009) of the influenza pandemic in Norway. Blue bars indicate considering immunity eight days and later after vaccination; red bars 15 days
and later.
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health authorities in other countries to set up such
registries. It is also important to consider including
information on underlying diseases in registries already
existing, in order to make it feasible to conduct more
complete VE estimations by controlling for potential
confounding factors that may affect the results obtained.
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